The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
It is the first time that the agency has authorized for marketing a next-generation sequencing test for HIV-1 resistance, the FDA noted.
The company said three clinical centers have validated the test in a prospective clinical trial involving more than 10,000 participants.
The team will combine Akoya's Vectra Polaris system with Precision for Medicine's Apostream tool to validate companion diagnostics and assess drug efficacy.
Under the new 15-year exclusive agreement, the test will become available through all of Sonic's clinical labs and anatomic pathology practices in the US.
Eurobio Scientific will also develop new test kits for the T-COR 8, a real-time PCR thermocycler originally developed for the US Army.
The firm is developing the test under a contract with the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
The acquisition of immunohistochemistry services provider QualTek will augment Discovery's existing histopathology services, the company said.
Researchers at MD Anderson Cancer Center found that somatic copy number alterations are more frequent in normal tissue surrounding tumor than in blood.
For fiscal 2020, BD provided guidance for revenue growth in the 4 to 4.5 percent range, or 5 to 5.5 percent on a currency-neutral basis.
The firm said that total revenue was lower than expected due to the timing of orders in its flow cytometry operations in the third quarter.
The company had a challenging fiscal first quarter due to the deletion of CPT codes that payors used to use to reimburse hereditary cancer testing.
NanoString logged $30.6 million in revenues in the third quarter, beating the Wall Street estimate of $28.1 million.
The Temple City, California-based NGS genetic testing firm more than doubled its number of billable tests compared to the prior-year period.
The consortium is comprised of researchers from Inova, Roswell Park Comprehensive Cancer Center, the Mayo Clinic, and MD Anderson Cancer Center.
The findings suggest a potential avenue to treat or prevent Alzheimer's disease, the researchers said.
An analysis of placental, parental, and cord blood samples indicated that an uptick in chromosomal instability in cleavage-stage in vitro fertilization embryos does not persist after birth.
Among the study's goals is to identify molecular signatures that can distinguish idiopathic pulmonary fibrosis from interstitial lung disease.
The five-year funding commitment represents a 5 percent increase over the previous grant period for the rapidly growing archive of 3D protein structures.
The company said it will use the net proceeds for general corporate purposes and to fund ongoing operations and expansion of its business.
Last week, GenomeWeb's readers were most interested in new products from Chinese sequencing instrument maker MGI Tech, including a portable sequencing system.
MGI Tech will market Pillar Biosciences' Onco/Reveal NGS panels alongside its high-throughput, automated library prep systems outside the US.
The approval allows the company to directly market and sell the CTC technology to labs and other institutions to develop and implement IVD tests.
The GenomeWeb index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.